Table 3.

Effects of 5,7-DHT lesioning on 5-HT, 5-HIAA, and norepinephrine levels in the frontal cortex, striatum, and dorsal and ventral hippocampus

5-HT5-HIAANorepinephrine
Vehicle5,7-DHTVehicle5,7-DHTVehicle5,7-DHT
Frontal cortex0.94 ± 0.020.10 ± 0.03*0.28 ± 0.010.04 ± 0.01*0.39 ± 0.070.29 ± 0.04
Striatum0.52 ± 0.030.10 ± 0.03*0.22 ± 0.020.05 ± 0.01*0.22 ± 0.020.26 ± 0.02
Dorsal hippocampus0.40 ± 0.040.04 ± 0.009*0.26 ± 0.020.02 ± 0.009*0.24 ± 0.020.20 ± 0.02
Ventral hippocampus0.61 ± 0.090.03 ± 0.008*0.31 ± 0.0090.02 ± 0.009*0.50 ± 0.100.43 ± 0.04

  • Mean (± SEM) levels of 5-HT, 5-HIAA, and norepinephrine (nanograms per milligram of wet weight tissue) in frontal cortex, striatum, and dorsal and ventral hippocampus of rats, 2 weeks after intracerebroventricular administration (5 μl volume) of either vehicle (0.2% ascorbic acid; n = 3) or 5,7-DHT (150 μ g; n = 3).

  • ↵*p < 0.01 relative to vehicle.